Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2012061074 - METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Publication Number WO/2012/061074
Publication Date 10.05.2012
International Application No. PCT/US2011/057519
International Filing Date 24.10.2011
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/2839
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2839against the integrin superfamily
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
G01N 2333/70503
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
G01N 2333/70546
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70546Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
G01N 2333/7056
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
Applicants
  • ELAN PHARMACEUTICALS, INC. [US]/[US] (AllExceptUS)
  • CHACKERIAN, Alissa, A. [US]/[US] (UsOnly)
Inventors
  • CHACKERIAN, Alissa, A.
Agents
  • BERNHARDT, Jeffery, P.
Priority Data
61/406,35825.10.2010US
61/406,36525.10.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
(FR) PROCÉDÉS DE DÉTERMINATION DE DIFFÉRENCES DANS L'ACTIVITÉ ALPHA-4 INTÉGRINE PAR LA CORRÉLATION DE DIFFÉRENCES DES TAUX DE SVCAM ET/OU DE SMADCAM
Abstract
(EN)
Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
(FR)
La présente invention concerne un procédé de surveillance de la modification des activités alpha-4 intégrine chez un individu par la corrélation avec le taux de molécule d'adhésion cellulaire vasculaire soluble (sVCAM) et/ou de molécule d'adhésion cellulaire adressine mucosale soluble (sMAdCAM). En particulier, ce procédé peut être utilisé, par exemple, pour évaluer la pharmacocinétique et la pharmacodynamique (PK/PD) d'un inhibiteur d'alpha-4 intégrine utilisé pour traiter une maladie associée à une inflammation pathologique ou chronique.
Latest bibliographic data on file with the International Bureau